A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
- PMID: 34602302
- DOI: 10.1016/j.vaccine.2021.08.010
A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future
Abstract
Improved influenza vaccines are urgently needed to reduce the burden of seasonal influenza and to ensure a rapid and effective public-health response to future influenza pandemics. The Influenza Vaccines Research and Development (R&D) Roadmap (IVR) was created, through an extensive international stakeholder engagement process, to promote influenza vaccine R&D. The roadmap covers a 10-year timeframe and is organized into six sections: virology; immunology; vaccinology for seasonal influenza vaccines; vaccinology for universal influenza vaccines; animal and human influenza virus infection models; and policy, finance, and regulation. Each section identifies barriers, gaps, strategic goals, milestones, and additional R&D priorities germane to that area. The roadmap includes 113 specific R&D milestones, 37 of which have been designated high priority by the IVR expert taskforce. This report summarizes the major issues and priority areas of research outlined in the IVR. By identifying the key issues and steps to address them, the roadmap not only encourages research aimed at new solutions, but also provides guidance on the use of innovative tools to drive breakthroughs in influenza vaccine R&D.
Keywords: Broadly protective influenza vaccines; Influenza; Pandemic preparedness; Roadmap; Seasonal influenza vaccines; Universal influenza vaccines.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Kristine Moore, Julia Ostrowsky, Angela Mehr, Michael Osterholm report financial support was provided by Wellcome Trust. Kristine Moore, Michael Osterholm report a relationship with Wellcome Trust that includes: funding grants. Coauthor received grants to the organization from Sanofi Pasteur, received grants from US CDC, PATH, Wellcome Trust, South African MRC. (CC) Coauthor is a former Director of one of the WHO International Reference Centres for influenza and was part of the biannual strain selection group. His family superannuation fund holds some shares in companies which produce vaccines, including Influenza vaccine (Pfizer, Merck and CSL) and specific antiviral agents (Vaxart). (IG) Coauthor is an independent Director of two organisations that support vaccine development, the Coalition for Epidemic Preparedness Innovations and MSD Wellcome Trust Hilleman Laboratories Pvt; Ltd. Neither is working on influenza vaccines. (GK) Coauthor has the following declarations: The Icahn School of Medicine at Mount Sinai has filed patent applications relating to universal influenza virus vaccines, SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which name me as inventor. I would also like to note the following, which could be perceived as a conflict of interest: I have previously published work on influenza virus vaccines with S. Gilbert (University of Oxford); have consulted for Curevac, Merck and Pfizer (before 2020); I am currently consulting for Pfizer, Seqirus and Avimex; my laboratory is collaborating with Pfizer on animal models of SARS-CoV-2 and with Dynavax on influenza virus vaccines; my laboratory is collaborating with N. Pardi at the University of Pennsylvania on mRNA vaccines against SARS-CoV-2 and my laboratory was working in the past with GlaxoSmithKline on the development of influenza virus vaccines and two of my mentees have recently joined Moderna. (FK)].
Similar articles
-
A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.Vaccine. 2023 Mar 24;41(13):2101-2112. doi: 10.1016/j.vaccine.2023.02.032. Epub 2023 Feb 21. Vaccine. 2023. PMID: 36870874 Free PMC article. Review.
-
Stakeholders' perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) - Results from a survey.Vaccine. 2016 Oct 26;34(45):5393-5399. doi: 10.1016/j.vaccine.2016.08.040. Epub 2016 Sep 16. Vaccine. 2016. PMID: 27646029 Free PMC article.
-
Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Biotechnol J. 2015 May;10(5):690-701. doi: 10.1002/biot.201400393. Epub 2015 Mar 2. Biotechnol J. 2015. PMID: 25728134 Review.
-
[Technical guidelines for seasonal influenza vaccination in China (2022-2023)].Zhonghua Yu Fang Yi Xue Za Zhi. 2022 Oct 6;56(10):1356-1386. doi: 10.3760/cma.j.cn112150-20220825-00840. Zhonghua Yu Fang Yi Xue Za Zhi. 2022. PMID: 36274602 Chinese.
-
Public Health-Driven Research and Innovation for Next-Generation Influenza Vaccines, European Union.Emerg Infect Dis. 2019 Feb;25(2):e180359. doi: 10.3201/eid2502.180359. Emerg Infect Dis. 2019. PMID: 30666948 Free PMC article.
Cited by
-
The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults.Adv Ther. 2024 Mar;41(3):945-966. doi: 10.1007/s12325-023-02770-0. Epub 2024 Jan 23. Adv Ther. 2024. PMID: 38261171 Free PMC article.
-
Understanding Attitudes Toward Influenza Vaccination: Insights from a Romanian Family Medicine Patient Population.Curr Health Sci J. 2023 Oct-Dec;49(4):517-523. doi: 10.12865/CHSJ.49.04.6. Epub 2023 Dec 29. Curr Health Sci J. 2023. PMID: 38559830 Free PMC article.
-
Recommendations on Rapid Diagnostic Point-of-care Molecular Tests for Respiratory Infections in the United Arab Emirates.Open Respir Med J. 2024 Dec 17;18:e18743064319029. doi: 10.2174/0118743064319029240815074449. eCollection 2024. Open Respir Med J. 2024. PMID: 39872239 Free PMC article. Review.
-
Understanding the Global Burden of Influenza in Adults Aged 18-64 years: A Systematic Literature Review from 2012 to 2022.Adv Ther. 2023 Oct;40(10):4166-4188. doi: 10.1007/s12325-023-02610-1. Epub 2023 Jul 20. Adv Ther. 2023. PMID: 37470942 Free PMC article.
-
Socio-economic inequalities in the use of flu vaccination in Europe: a multilevel approach.Health Econ Rev. 2024 Jul 31;14(1):61. doi: 10.1186/s13561-024-00535-1. Health Econ Rev. 2024. PMID: 39083186 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical